Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

This review focuses on research in epidemiology, neuropathology, molecular biology, and
genetics regarding the hypothesis that pathogens interact with susceptibility genes and are …

Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused
ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier …

In 1906, Alois Alzheimer described the neuropathology of the disease that was to bear his
name. 1 Subsequently, our understanding of Alzheimer disease (AD) has grown …

Current approved drug treatments for Alzheimer disease (AD) include cholinesterase
inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist …

The identification of amyloid-β precursor protein (APP) pathogenic mutations in familial early
onset Alzheimer's disease (AD), along with knowledge that amyloid-β (Aβ) was the principle …

With increasing feasibility of predicting conversion of mild cognitive impairment to dementia
based on biomarker profiling, the urgent need for efficacious disease‐modifying compounds …

Preclinical and clinical data support the use of focused ultrasound (FUS), in the presence of
intravenously injected microbubbles, to safely and transiently increase the permeability of …

Intravenous immunoglobulin (IVIg) is currently evaluated in clinical trials for the treatment of
various disorders of the central nervous system. To assess its capacity to reach central …

Immunotherapy is currently being intensively explored as much-needed disease-modifying
treatment for neurodegenerative diseases. While Alzheimer's disease (AD) has been the …